AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

ALLIANCE PHARMA PLC

Board/Management Information Jul 10, 2015

7478_rns_2015-07-10_db3ae703-f496-4382-bdb7-bee00c93ac70.html

Board/Management Information

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 6601S

Alliance Pharma PLC

10 July 2015

For immediate release 10 July 2015

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Appointment of Finance Director

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, is pleased to announce the appointment of Andrew Franklin as Finance Director.  Andrew will join the Company and the Board with effect from 28 September 2015.

From 2010 to 2012, Andrew was finance director and company secretary of Genzyme Therapeutics Ltd, the UK & Ireland subsidiary of Genzyme Corporation, the biotechnology company acquired by Sanofi.  Prior to that, he gained 12 years' pharmaceutical experience with Wyeth in a variety of senior financial positions.  Andrew joins Alliance from Panasonic Europe Ltd, where he was general manager, European tax and accounting.

He qualified as a chartered accountant with Arthur Andersen in 1992 having graduated in 1988 with a first class degree in civil engineering from University of Wales, Cardiff.

Commenting on the appointment, John Dawson, Chief Executive Officer of Alliance, said: "We welcome Andrew to Alliance as our new Finance Director. He brings considerable experience, having operated for 14 years in senior financial roles in the pharmaceutical industry. Andrew will be a strong addition to the Alliance team."

The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies. Andrew Timothy Franklin, aged 49 years, has been a director of the following companies during the five years preceding the date of this announcement:

Current directorships

None

Past directorships

Genzyme Therapeutics Limited

Bioenvision Limited 

There is no further information to be disclosed pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies.

For further information:

### Alliance Pharma plc ### + 44 (0) 1249 466966
John Dawson, Chief Executive
### Buchanan ### + 44 (0) 20 7466 5000
Mark Court / Sophie Cowles / Jane Glover
Numis Securities Limited + 44 (0) 20 7260 1000
Nominated Adviser: Michael Meade / Freddie Barnfield
Corporate Broking: David Poutney

Notes to editors:

About Alliance

Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and owns or licenses the rights to more than 60 pharmaceutical products and continues to explore opportunities to expand the range.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOARLMITMBTMBFA

Talk to a Data Expert

Have a question? We'll get back to you promptly.